{"id":"NCT02151981","sponsor":"AstraZeneca","briefTitle":"AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer","officialTitle":"A Phase III, Open Label, Randomized Study of AZD9291 Versus Platinum-Based Doublet Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene (AURA3).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-08-04","primaryCompletion":"2016-04-15","completion":"2023-12-15","firstPosted":"2014-06-02","resultsPosted":"2017-07-21","lastUpdate":"2025-01-07"},"enrollment":421,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anticancer Treatment"],"interventions":[{"type":"DRUG","name":"Chemotherapy","otherNames":["Osimertinib","Platinum-based Doublet-Chemotherapy"]},{"type":"DRUG","name":"Cross-over to Osimertinib","otherNames":[]}],"arms":[{"label":"Osimertinib","type":"EXPERIMENTAL"},{"label":"Platinum-based doublet chemotherapy","type":"ACTIVE_COMPARATOR"}],"summary":"A Phase III, Open Label, Randomized Study of Osimertinib versus Platinum-Based Doublet Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene","primaryOutcome":{"measure":"Progression Free Survival (PFS) by Investigator Assessment","timeFrame":"RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).","effectByArm":[{"arm":"Osimertinib 80mg","deltaMin":10.1,"sd":null},{"arm":"Chemotherapy","deltaMin":4.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":7},"locations":{"siteCount":150,"countries":["United States","Australia","Canada","China","France","Germany","Hong Kong","Hungary","Italy","Japan","Mexico","Netherlands","Russia","South Korea","Spain","Sweden","Taiwan","United Kingdom"]},"refs":{"pmids":["40311309","35575012","35379563","32861806","31769875","30059262","29733770","29697876","27959700","26159065"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=2892&filename=D5160C00003AURA3_CSPredacted.pdf","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5160C00003&amp;attachmentIdentifier=7ea80d41-31f4-44b2-8b95-0a1b2d616487&amp;fileName=D5160C00003_SAP_ed4_redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5160C00003&amp;attachmentIdentifier=d5305855-1732-4dc0-bcfb-8c90e82a918f&amp;fileName=d5160c00003-study-synopsis_DCO4_20Aug2019_-_Redactednew.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":84,"n":279},"commonTop":["Diarrhoea","Nausea","Decreased appetite","Constipation","Fatigue"]}}